Long-term HIV treatment may reduce risk for atherosclerosis

Aug 04, 2008

Antiretroviral drugs for HIV do not increase the risk for coronary atherosclerosis, a central risk factor for heart disease, according to a study led by the University of Pittsburgh Graduate School of Public Health to be published in the Aug. 8 issue of the journal AIDS and available online today. The results further suggest that antiretroviral therapy may offer men with HIV some protection against atherosclerosis – hardening of the arteries, caused in part by high levels of cholesterol, smoking and other lifestyle factors.

The study, part of the Multicenter AIDS Cohort Study (MACS) initiated in 1983, measured levels of coronary artery calcification (CAC) in nearly 950 HIV-positive and HIV-negative men by CT scanning completed between 2004 and 2006. Controlling for traditional atherosclerosis risk factors such as age, family history, smoking and blood pressure, the study team found that CAC scores were almost 60 percent lower in HIV-positive men who received highly active antiretroviral therapy (HAART) for more than eight years compared to HIV-negative men.

HAART, a course of treatment that involves the combination of three or more antiretrovirals, has been associated with an increase in cholesterol and other factors associated with atherosclerosis, leading some to question whether long-term use increases the risk of heart attack.

"When we first prescribed highly active antiretroviral therapy for HIV in 1995, we were concerned about how these drugs changed lipid levels in patients and whether they would increase atherosclerosis and ultimately lead to serious heart disease," said Lawrence Kingsley, Ph.D., study lead author and associate professor, Departments of Infectious Diseases and Microbiology and Epidemiology, University of Pittsburgh Graduate School of Public Health. "While some studies have found an association between these antiretroviral treatments and increased risk of cardiovascular disease, we believe our findings should reassure clinicians that using antiretroviral therapy over time does not appear to put patients at greater risk for coronary atherosclerosis and may, in fact, be more beneficial than we had initially thought."

The study also found that for both HIV-positive and HIV-negative men, older age was most strongly associated with the presence of coronary atherosclerosis. Smoking, lipid abnormalities and family history also played a role.

"This was not surprising since these are the major risk factors for atherosclerosis in the general population," said Dr. Kingsley. "The purpose of our study, however, was to investigate whether long-term HAART usage was a major risk factor."

"These results could be due, in part, to lower lipid values of HIV infected men prior to beginning antiretroviral therapy and high use of lipid-lowering drugs. The key is that controlling risk factors for atherosclerosis should be a priority," added Lewis Kuller, M.D., Dr.P.H, study co-author and professor of epidemiology, University of Pittsburgh Graduate School of Public Health.

Dr. Kingsley concluded, "What remains to be determined is whether use of the newest antiretroviral therapies confers an even better outcome and whether lipid-lowering therapies will further improve cardiovascular risk in the HIV-infected population. Our future research will address these questions."

Source: University of Pittsburgh

Explore further: So much has changed since the first HIV test was approved 30 years ago

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Preventing one case of HIV saves over $225K, study shows

Feb 27, 2015

How much money would be saved if one high-risk person was prevented from contracting HIV in the United States? A new study led by a researcher at Weill Cornell Medical College and published online Feb. 24 in Medical Care, answer ...

Research captures transient details of HIV genome packaging

Feb 27, 2015

Once HIV-1 has hijacked a host cell to make copies of its own RNA genome and viral proteins, it must assemble these components into new virus particles. The orchestration of this intricate assembly process falls to a viral ...

Could an HIV drug beat strep throat, flesh-eating bacteria?

Feb 25, 2015

With antibiotic resistance on the rise, scientists are looking for innovative ways to combat bacterial infections. The pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.